Home » Stocks » KDMN

Kadmon Holdings, Inc. (KDMN)

Stock Price: $4.17 USD 0.10 (2.46%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $4.09 -0.08 (-1.92%) Dec 4, 6:34 PM

KDMN Stock Price Chart

Key Info

Market Cap 744.96M
Revenue (ttm) 12.08M
Net Income (ttm) -94.88M
Shares Out 169.31M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $4.17
Previous Close $4.07
Change ($) 0.10
Change (%) 2.46%
Day's Open 4.11
Day's Range 4.07 - 4.23
Day's Volume 2,225,277
52-Week Range 2.44 - 5.26

KDMN Stock News

The Motley Fool - 3 months ago

The developmental biotech reported quarterly results and gave investors updates on its drug pipeline.

Investors Business Daily - 4 months ago

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Other stocks mentioned: BMY, PTGX
InvestorPlace - 5 months ago

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: CORT, DVAX, GTHX, IMGN, SUPN, VRTX
InvestorPlace - 6 months ago

In times of market turbulence, cheap stocks offer a unique way to escape the broad moves up and down and instead benefit from big potential. The post 7 Cheap Stocks to Buy With Great Potentia...

Other stocks mentioned: IAG, IMGN, INFN, PLUG, SVM, UMC
The Motley Fool - 6 months ago

The company reported positive results from a clinical trial for one of its most promising pipeline candidates.

Kiplinger - 6 months ago

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, FIXX, GTHX, IMGN, VKTX
InvestorPlace - 8 months ago

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Other stocks mentioned: ARCT, AUPH, CCXI, NVAX, NVRO, TMO
Seeking Alpha - 8 months ago

There are high chances of KD025 securing FDA approval in cGVHD indication.

InvestorPlace - 10 months ago

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

Other stocks mentioned: CDTX, CPE, NEX, OVID, QEP
Seeking Alpha - 10 months ago

Kadmon: Updates To Thesis, Pivotal cGVHD Data Impresses

Zacks Investment Research - 11 months ago

Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.

GuruFocus - 1 year ago

Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?

Other stocks mentioned: ET, REPL
The Motley Fool - 1 year ago

Positive clinical trial results for the biopharmaceutical company's lead candidate, KD025, are driving investors' optimism.

Market Watch - 1 year ago

Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary end...

The Motley Fool - 1 year ago

Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.

Other stocks mentioned: DRRX
Zacks Investment Research - 1 year ago

Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

Zacks Investment Research - 1 year ago

Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Shares have lost a third of their value since my initial article.

Zacks Investment Research - 1 year ago

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

About KDMN

Kadmon Holdings, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the trea... [Read more...]

Industry
Biotechnology
IPO Date
Jul 27, 2016
CEO
Dr. Harlan W. Waksal
Employees
115
Stock Exchange
NASDAQ
Ticker Symbol
KDMN
Full Company Profile

Financial Performance

In 2019, KDMN's revenue was $5.10 million, an increase of 264.97% compared to the previous year's $1.40 million. Losses were -$61.37 million, 13.1% more than in 2018.

Financial Statements